Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial

OBJECTIVE To investigate the efficacy and safety of dasiglucagon, a novel stable glucagon analog in a liquid formulation, in Roux-en-Y gastric bypass (RYGB)-operated individuals suffering from postbariatric hypoglycemia (PBH). RESEARCH DESIGN AND METHODS In a randomized, double-blind, placebo-controlled, crossover trial, 10 RYGB-operated participants with continuous glucose monitoring-verified PBH were randomly assigned to 3 trial days, each consisting of a 240-min standardized liquid mixed-meal test with the subcutaneous injection of placebo or 80 mu g or 200 mu g dasiglucagon. RESULTS Compared with placebo, treatment with both 80 and 200 mu g dasiglucagon raised nadir plasma glucose (PG) (placebo: 3.0 0.2 mmol/L [mean +/- SEM]; 80 mu g dasiglucagon: 3.9 +/- 0.3 mmol/L, P = 0.002; 200 mu g dasiglucagon: 4.5 +/- 0.2 mmol/L, P = 0.0002) and reduced time in hypoglycemia (PG <3.9 mmol/L) by 70.0 min (P = 0.030 and P = 0.008). CONCLUSIONS Single-dose administration of dasiglucagon effectively mitigated postprandial hypoglycemia.

Automated summary

This study investigated the efficacy and safety of a novel stable glucagon analog, dasiglucagon, in individuals who had undergone Roux-en-Y gastric bypass (RYGB) and suffered from postbariatric hypoglycemia (PBH). The results demonstrated that a single-dose administration of dasiglucagon effectively mitigated postprandial hypoglycemia.